spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online June 15, 2006
Journal of Experimental Biology 209, 2525-2534 (2006)
Published by The Company of Biologists 2006
doi: 10.1242/jeb.02274
This Article
Right arrow Summary Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaufman, W. R.
Right arrow Articles by Minion, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaufman, W. R.
Right arrow Articles by Minion, J. L.

Pharmacological characterization of the ergot alkaloid receptor in the salivary gland of the ixodid tick Amblyomma hebraeum

W. Reuben Kaufman* and Jessi L. Minion

Department of Biological Sciences, University of Alberta, Edmonton, Alberta, T6G 2E9, Canada


Figure 1
View larger version (33K):

[in a new window]
  		Fig. 1. (A–L) Ergot alkaloids tested on tick salivary glands. The agonist activity for each is indicated in parentheses. All structures compiled from Berde and Schild (Berde and Schild, 1978Go). Reproduced with kind permission of Springer Science and Business Media.

 

Figure 2
View larger version (23K):

[in a new window]
  		Fig. 2. Complete agonists. Dose–response curves for the indicated drugs were constructed as described in Materials and methods. The standard error of the mean (s.e.m.) is shown wherever it exceeds the size of the symbol.

 

Figure 3
View larger version (19K):

[in a new window]
  		Fig. 3. Incomplete agonists. Dose–response curves for the indicated drugs were conducted as described in Materials and methods. The s.e.m. is shown wherever it exceeds the size of the symbol. The data for 5-hydroxytrypamine (5-HT) includes only those glands that showed some response to 5-HT.

 

Figure 4
View larger version (19K):

[in a new window]
  		Fig. 4. Partial agonists. Dose–response curves for the indicated drugs were conducted as described in Materials and methods. The s.e.m. is shown wherever it exceeds the size of the symbol.

 

Figure 5
View larger version (23K):

[in a new window]
  		Fig. 5. Inhibition of ergonovine (ErN) by putative antagonists, ergothioneine and (+/–)-sulpiride. The s.e.m. is shown wherever it exceeds the size of the symbol.

 

Figure 6
View larger version (28K):

[in a new window]
  		Fig. 6. Inhibition of (A) dopamine (DA) and (B) ergonovine (ErN) by the partial agonists, bromocriptine and methysergide. The s.e.m. is shown wherever it exceeds the size of the symbol.

 

Figure 7
View larger version (27K):

[in a new window]
  		Fig. 7. Potentiation of (A) dopamine (DA) but not (B) ergonovine (ErN) by the putative PKC inhibitor calphostin C. The s.e.m. is shown wherever it exceeds the size of the symbol.

 




© The Company of Biologists Ltd 2006